Delamanid expanded access novel treatment of drug resistant tuberculosis

Roxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS Foundation Trust, London, UKAbstract: Tuberculosis (TB...

Full description

Bibliographic Details
Main Authors: Rustomjee R, Zumla A
Format: Article
Language:English
Published: Dove Medical Press 2015-10-01
Series:Infection and Drug Resistance
Online Access:https://www.dovepress.com/delamanid-expanded-access-novel-treatment-of-drug-resistant-tuberculos-peer-reviewed-article-IDR
id doaj-745bf430c003431483111209b8f86079
record_format Article
spelling doaj-745bf430c003431483111209b8f860792020-11-24T22:08:42ZengDove Medical PressInfection and Drug Resistance1178-69732015-10-012015default35936624384Delamanid expanded access novel treatment of drug resistant tuberculosisRustomjee RZumla ARoxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS Foundation Trust, London, UKAbstract: Tuberculosis (TB) remains a global emergency and is one of the most common infectious disease causes of death in developing countries. Current treatment regimens for multi-drug resistant TB are associated with low treatment success rates, are toxic, and require long duration of treatment. The need for shorter and more effective treatment regimens is urgent. Delamanid (Deltyba, or formerly known as OPC-67683) is a new dihydro-imidazooxazole anti-TB drug active against resistant forms of pulmonary TB. Delamanid kills Mycobacterium tuberculosis by inhibiting the synthesis of mycolic acids required for cell wall synthesis. Whilst delamanid has been included in the WHO Model List of Essential Medicine by the World Health Organization Expert Committee on Selection and Use of Essential Medicines and in international guidance for the treatment of multi-drug resistant TB since April 2014, its access in countries with the greatest need, has proven challenging. This review provides an update on currently available clinical safety and efficacy data on delamanid and offers a discussion on research priorities and recommendations for expedited, expanded access.Keywords: delamanid, tuberculosis, drug resistance, MDR-TB, expanded accesshttps://www.dovepress.com/delamanid-expanded-access-novel-treatment-of-drug-resistant-tuberculos-peer-reviewed-article-IDR
collection DOAJ
language English
format Article
sources DOAJ
author Rustomjee R
Zumla A
spellingShingle Rustomjee R
Zumla A
Delamanid expanded access novel treatment of drug resistant tuberculosis
Infection and Drug Resistance
author_facet Rustomjee R
Zumla A
author_sort Rustomjee R
title Delamanid expanded access novel treatment of drug resistant tuberculosis
title_short Delamanid expanded access novel treatment of drug resistant tuberculosis
title_full Delamanid expanded access novel treatment of drug resistant tuberculosis
title_fullStr Delamanid expanded access novel treatment of drug resistant tuberculosis
title_full_unstemmed Delamanid expanded access novel treatment of drug resistant tuberculosis
title_sort delamanid expanded access novel treatment of drug resistant tuberculosis
publisher Dove Medical Press
series Infection and Drug Resistance
issn 1178-6973
publishDate 2015-10-01
description Roxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS Foundation Trust, London, UKAbstract: Tuberculosis (TB) remains a global emergency and is one of the most common infectious disease causes of death in developing countries. Current treatment regimens for multi-drug resistant TB are associated with low treatment success rates, are toxic, and require long duration of treatment. The need for shorter and more effective treatment regimens is urgent. Delamanid (Deltyba, or formerly known as OPC-67683) is a new dihydro-imidazooxazole anti-TB drug active against resistant forms of pulmonary TB. Delamanid kills Mycobacterium tuberculosis by inhibiting the synthesis of mycolic acids required for cell wall synthesis. Whilst delamanid has been included in the WHO Model List of Essential Medicine by the World Health Organization Expert Committee on Selection and Use of Essential Medicines and in international guidance for the treatment of multi-drug resistant TB since April 2014, its access in countries with the greatest need, has proven challenging. This review provides an update on currently available clinical safety and efficacy data on delamanid and offers a discussion on research priorities and recommendations for expedited, expanded access.Keywords: delamanid, tuberculosis, drug resistance, MDR-TB, expanded access
url https://www.dovepress.com/delamanid-expanded-access-novel-treatment-of-drug-resistant-tuberculos-peer-reviewed-article-IDR
work_keys_str_mv AT rustomjeer delamanidexpandedaccessnoveltreatmentofdrugresistanttuberculosis
AT zumlaa delamanidexpandedaccessnoveltreatmentofdrugresistanttuberculosis
_version_ 1725815197028843520